Bristol-Myers Squibb Reports Strong Q3 2024 Results
Company Announcements

Bristol-Myers Squibb Reports Strong Q3 2024 Results

Bristol-Myers Squibb ( (BMY) ) just unveiled an announcement.

Bristol Myers Squibb reported robust third-quarter results for 2024, with revenues rising to $11.9 billion, marking an 8% increase (10% when adjusted for foreign exchange). The company’s Growth Portfolio and U.S. approval of Cobenfy for schizophrenia played significant roles in this performance. Despite some challenges like generic erosion of Sprycel, the firm saw strong cash flow and increased revenue guidance. Investors should note the balance of GAAP and non-GAAP figures, reflecting strategic financial moves and a focus on sustainable growth.

For detailed information about BMY stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyElliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz
TheFlyBristol Myers price target raised to $61 from $57 at BMO Capital
TheFlyNvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App